Xenetic Biosciences, Inc.
Genetically modified yeast platform for biopharmaceutical manufacturing and cancer immunotherapy
- Sector
- Biotech
- Headquarters
- FRAMINGHAM, MA
- Latest Form D
- $489K, Oct 2022
- Total capital
- $17.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $17.6M
- 5 Form D · last Oct 2022
- 48 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 5 pending · first 2019
- Rank in peer group#73 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$489K
- Private capital raisedForm D · SEC · 4th filing$866K
- Private capital raisedForm D · SEC · 3rd filing$12.5M
- Private capital raisedForm D · SEC · 2nd filing$252K
- Private capital raisedForm D · SEC · 1st filing$3.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#73 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Adam LogalDirectorNamed in SEC Form D filings
- Alexey VinogradovDirectorNamed in SEC Form D filings
- Curtis LockshinExecutive OfficerNamed in SEC Form D filings
- Dmitry GenkinDirectorNamed in SEC Form D filings
- Firdaus DastoorDirectorNamed in SEC Form D filings
- Grigory BorisenkoDirectorNamed in SEC Form D filings
Show all 11 people
- James CallawayDirectorNamed in SEC Form D filings
- James ParslowExecutive OfficerNamed in SEC Form D filings
- Jeffrey EisenbergExecutive Officer, DirectorNamed in SEC Form D filings
- Roger KornbergDirectorNamed in SEC Form D filings
- Roman KnyazevDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 6- PendingChimeric Antigen Receptor T-cell Treatments Targeted To Chromatin Fragments And Extracellular TrapsUSPTOApplication 18843056
- PendingMethods Of Using Glycopolysialylated Therapeutic ProteinsUSPTOApplication 18603127
- PendingMethods Of Using Glycopolysialylated Therapeutic ProteinsUSPTOApplication 17428574
Show all 6 patent records
- Chimeric Antigen Receptor T-cell Treatments Targeted To Chromatin Fragments And Extracellular TrapsMay 29, 2025 · Application 18843056Pending
- Methods Of Using Glycopolysialylated Therapeutic ProteinsAug 15, 2024 · Application 18603127Pending
- Methods Of Using Glycopolysialylated Therapeutic ProteinsApr 7, 2022 · Application 17428574Pending
- Compositions and Methods for Administering Insulin or Insulin-Like Protein to the BrainJan 29, 2019 · US 10,188,739Granted
- Methods Of Using Glycopolysialylated Therapeutic ProteinsApplication PCTUS2020016500Pending
- Compositions And Methods For Administering Insulin Or Insulin-like Protein To The BrainApplication PCTUS2015017819Pending
Related companies, and why
- Q32 BioSimilar federal contract value in Biotech · null in contracts
- Mytos, Inc.Similar federal contract value in Biotech · null in contracts
- CollPlant Biotechnologies LtdSimilar federal contract value in Biotech · null in contracts
- Vigeo Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Frame Technology, Inc.Similar federal contract value in Biotech · null in contracts
- Autonomy Bio Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .